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Background
In September 2000, the National Institute for Health and Clinical Excellence (NICE) published guidance on the use of implantable cardioverter defibrillators (ICDs) for arrhythmias. That guidance relied heavily on a small number of relatively large-scale randomised controlled trials (RCTs) of ICDs compared with conventional management conducted principally in North America. Questions remain about the generalisability of their results to the UK, particularly the associated analyses of costeffectiveness. This study was designed not simply to update the existing systematic review of published literature, but also to collect original data relating to the UK to use with international trial data to model the costeffectiveness of ICDs in a UK context. Thus, this report contains a combination of an updating of the systematic review evidence on the effectiveness, health-related quality of life (HRQoL) and cost-effectiveness of ICDs; compilation of new data on the service provision in the UK; and on the clinical characteristics, survival, quality of life and costs of ICD patients in the UK, and a new cost-effectiveness model using both international RCT and UK-specific data.
Updated systematic reviews of studies of effectiveness, quality of life and cost-effectiveness
Objectives
To update the earlier review on clinical effectiveness and cost-effectiveness of ICDs compared with conventional therapy of patients at risk of sudden cardiac death (SCD) due to arrhythmias.
Methods
Electronic databases and reference lists were searched from November 1999 to March 2003 for RCTs, systematic reviews and meta-analyses following recognised principles. Cost-effectiveness studies pre-dating the availability of RCT data were excluded.
Results
Five original clinical studies meeting these criteria were identified that had been published since the previous review: three RCTs of effectiveness (CASH, MADIT II and CAT) and two RCT-based studies of HRQoL (based on the AVID and CIDS trials). In addition, there was one systematic review and one meta-analysis of secondary prevention trials. Eight economic studies were appraised, of which four were directly based on an RCT, two on specific registries/databases and two models used multiple sources. None of the economic analyses could be directly applied to the UK.
Conclusions
There is increasingly strong RCT evidence for the survival benefits of ICDs compared with medical management of ventricular arrhythmias following survival of cardiac arrest and in preventing SCD in those at high risk. The evidence on impact on HRQoL is conflicting and relatively weak. The estimates of cost-effectiveness vary considerably, not least because of the different time-horizons considered and the need to make assumptions on long-term relative effectiveness.
Data on service provision in the UK

Objectives
To review the current use of, and service provision for, ICDs in the UK.
Methods
Multiple published data sources were used and a survey of ICD centres was conducted.
Results
The multiple sources of routine data available (including the national ICD database) provide an imperfect picture of the need for and use of ICDs. Implantation rates have been rising to a rate of around 20 per million population. Mean age is increasing and most ICDs are implanted into men aged 45-74 years. There is significant geographical variation. A survey of 41 UK centres provided additional evidence, particularly of variation in level of activity and resourcing. 
Methods
Basic data were obtained from two major implanting centres including 535 patients (about 10% of overall UK activity) implanted between 1991 and 2002, and retrieval of fuller data, on patient characteristics, management and resource use, from patient notes for a sample of 426 patients was attempted. A cross-sectional survey collected HRQoL data (using the Nottingham Health Profile, Short Form 36, Hospital Anxiety and Depression questionnaire, EuroQoL 5 Dimensions and disease-specific questions) on a sample of 229 patients.
Results
Most detailed data were obtained for 380 patients (89%). The postal survey produced a 73% response rate. Demographic characteristics of these patients were similar to ICD recipients in the UK as a whole and patients included in secondary prevention RCTs. Mean actuarial survival at 1, 3 and 5 years was 92%, 86% and 71%, respectively. Patient age at implantation and functional status significantly affected survival.
Levels of most of the HRQoL measures were lower than for a UK general population There was no evidence of a change with time from implantation. Patients who had suffered ICD shocks had significantly poorer HRQoL. Most patients nevertheless expressed a high level of satisfaction with ICD therapy.
Mean initial costs of implantation showed little variation between centres (£23,300 versus £22,100) or between earlier and more recent implants. There appeared to be greater variation between patients presenting along different pathways. Postdischarge costs (tests, medications and follow-up consultations) and costs of additional hospitalisations were also calculated.
Conclusions
These data showed the degree of similarity of the UK ICD recipients to those in the secondary prevention trials, and identified the main characteristics that appear to be systematically related to survival [age at implant and left ventricular ejection fraction (LVEF)], to HRQoL (number of shocks) and to costs of implantation (patient pathways). These data provide key parameter values for the UK relevant model of cost-effectiveness.
Cost-effectiveness model for the UK Objective
To estimate the cost-effectiveness of ICDs compared with antiarrhythmic drug treatment in the UK, in secondary prevention patients at risk of SCD.
Methods
A Markov model combined UK patient data with data from published RCTs to estimate incremental costs per life-year or quality-adjusted life-year (QALY) gained.
Results
Over a 20-year horizon, mean discounted incremental costs were £70,900 (£35,000-142,400). Mean discounted gain was 1.24 years (0.29-2.32) or 0.93 QALYs. Cost-effectiveness was most favourable for men aged over 70 years with an LVEF below 35%. If the treatment effect were to continue, then the cost per life-year over a lifetime might fall to around £32,000.
Conclusions
Although there is considerable uncertainty involved in modelling beyond the experience of the trials, the results suggest that ICDs, as currently applied in the UK, are not cost-effective by conventional standards.
Addendum Objective
To summarise and discuss new primary and secondary research published while the main study was under review. 
Methods
Results
Five RCTs of ICDs, a meta-analysis and, a costeffectiveness analysis of ICDs used in primary prevention, and a meta-analysis of ICDs in patients with non-ischaemic cardiomyopathy have been published recently. These trials provide confirmation of survival benefit of ICDs used in primary prevention in both ischaemic and nonischaemic cardiomyopathy patients. Costs per QALY ranged from US$34,000 in older trials (MADIT, MUSTT) to controls being both less expensive and more effective (CABG Patch, DINAMIT). More recent trials estimated cost per QALY between $50,300 and $70,200. The inconsistency in evidence for a HRQoL benefit has not been resolved and further work on risk stratification is necessary.
Conclusions
Overall, the survival benefit and cost-effectiveness estimates for primary prevention patients are similar to those for secondary prevention patients in the UK.
Overall conclusions
The evidence of short-to medium-term patient benefit from ICDs is strong but cost-effectiveness modelling indicates that the extent of that benefit is probably not sufficient to make the technology cost-effective as used currently in the UK. One reason is the high rates of postimplantation hospitalisation. Better patient targeting and efforts to reduce the need for such hospitalisation may improve cost-effectiveness.
Recommendations for further research
Further cost-effectiveness modelling, underpinned by an improved ICD database with reliable longterm follow-up, is required. This can now begin fully to address the cost-effectiveness of primary prevention, particularly as the results from other primary prevention trials are added to those from MADIT II.
The absence of a robust measure of the incidence of SCDs is noted. This may be an area where further organisational changes with improved data collection would help. However, to be effective this will require the co-ordination of information from a wide range of sources, including the records of pathology services and coroners' offices.
